Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,170
  • Shares Outstanding, K 51,496
  • Annual Sales, $ 200 K
  • Annual Income, $ -28,960 K
  • 60-Month Beta -0.36
  • Price/Sales 97.59
  • Price/Cash Flow N/A
  • Price/Book 4.70
Trade AIM with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.64
  • Most Recent Earnings $-0.12 on 05/16/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3054 +48.85%
on 05/29/24
0.4690 -3.07%
on 06/06/24
+0.0702 (+18.26%)
since 05/14/24
3-Month
0.3054 +48.85%
on 05/29/24
0.6200 -26.68%
on 04/11/24
+0.1211 (+36.31%)
since 03/14/24
52-Week
0.3054 +48.85%
on 05/29/24
0.7487 -39.28%
on 07/21/23
-0.0023 (-0.50%)
since 06/14/23

Most Recent Stories

More News
Biotech Sector Delivering Increased Optimism in Battle Against Pancreatic Cancer

USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival rate for those diagnosed with pancreatic has increased to 12%—representing an increase...

NVS : 105.36 (-0.62%)
ONCY : 1.0100 (-1.94%)
ONC.TO : 1.40 (unch)
RHHBY : 34.6600 (+0.41%)
BMEA : 5.90 (+1.55%)
AIM : 0.4393 (+6.86%)
AZN : 79.37 (-0.20%)
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 14, 2023 – USA News Group  –  Optimism is on the rise as the American Cancer Society is reporting that the five-year...

NVS : 105.36 (-0.62%)
ONCY : 1.0100 (-1.94%)
ONC.TO : 1.40 (unch)
RHHBY : 34.6600 (+0.41%)
BMEA : 5.90 (+1.55%)
AIM : 0.4393 (+6.86%)
AZN : 79.37 (-0.20%)
AIM ImmunoTech Announces Corporate Governance Enhancements

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the following corporate governance enhancements:

AIM : 0.4393 (+6.86%)
AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that shareholders have re-elected all three of the Company’s directors, Stewart L. Appelrouth, Thomas K. Equels...

AIM : 0.4393 (+6.86%)
Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group’s Nominations Valid

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”) today announced that the Delaware Court of Chancery has denied Jonathan Jorgl’s motion for a mandatory preliminary injunction...

AIM : 0.4393 (+6.86%)
AIM ImmunoTech Board Issues Letter to Shareholders

The Board of Directors (“Board”) of AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”) today issued a letter to shareholders to correct the record around recent false and misleading...

AIM : 0.4393 (+6.86%)
AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

The Board of Directors (“Board”) of AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today announced that the Company has filed its Definitive Proxy Statement in connection...

AIM : 0.4393 (+6.86%)
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders,...

AIM : 0.4393 (+6.86%)
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of...

AIM : 0.4393 (+6.86%)
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and...

AIM : 0.4393 (+6.86%)

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 0.4709
2nd Resistance Point 0.4430
1st Resistance Point 0.4270
Last Price 0.4393
1st Support Level 0.3831
2nd Support Level 0.3552
3rd Support Level 0.3392

See More

52-Week High 0.7487
Fibonacci 61.8% 0.5794
Fibonacci 50% 0.5271
Fibonacci 38.2% 0.4747
Last Price 0.4393
52-Week Low 0.3054

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar